XML 83 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Considerations (Details 5) - USD ($)
Jun. 30, 2020
Jun. 30, 2019
MiOXSYS patent (Luoxis patents) $ 11,081,048 $ 220,611
Fair Value, Measurements, Nonrecurring    
MiOXSYS patent (Luoxis patents) 0  
Debt 982,076  
Total 96,410,697  
Level 1 | Fair Value, Measurements, Nonrecurring    
MiOXSYS patent (Luoxis patents) 0  
Debt 0  
Total 0  
Level 2 | Fair Value, Measurements, Nonrecurring    
MiOXSYS patent (Luoxis patents) 0  
Debt 0  
Total 0  
Level 3 | Fair Value, Measurements, Nonrecurring    
MiOXSYS patent (Luoxis patents) 0  
Debt 982,076  
Total 96,410,697  
Cerecor, Inc. | Fair Value, Measurements, Nonrecurring    
Product technology rights 22,700,000  
Goodwill 19,453,135  
Fixed payment arrangements 29,837,853  
Cerecor, Inc. | Level 1 | Fair Value, Measurements, Nonrecurring    
Product technology rights 0  
Goodwill 0  
Fixed payment arrangements 0  
Cerecor, Inc. | Level 2 | Fair Value, Measurements, Nonrecurring    
Product technology rights 0  
Goodwill 0  
Fixed payment arrangements 0  
Cerecor, Inc. | Level 3 | Fair Value, Measurements, Nonrecurring    
Product technology rights 22,700,000  
Goodwill 19,453,135  
Fixed payment arrangements 29,837,853  
Innovus Pharmaceuticals | Fair Value, Measurements, Nonrecurring    
Customer lists 390,000  
Product distribution rights (trademarks and patents) 11,354,000  
Goodwill 8,637,272  
Notes payable 3,056,361  
Innovus Pharmaceuticals | Level 1 | Fair Value, Measurements, Nonrecurring    
Customer lists 0  
Product distribution rights (trademarks and patents) 0  
Goodwill 0  
Notes payable 0  
Innovus Pharmaceuticals | Level 2 | Fair Value, Measurements, Nonrecurring    
Customer lists 0  
Product distribution rights (trademarks and patents) 0  
Goodwill 0  
Notes payable 0  
Innovus Pharmaceuticals | Level 3 | Fair Value, Measurements, Nonrecurring    
Customer lists 390,000  
Product distribution rights (trademarks and patents) 11,354,000  
Goodwill 8,637,272  
Notes payable $ 3,056,361